Close Menu
    What's Hot

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026

    US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

    August 13, 2026

    Editor’s Letter – Volume 2, Issue 8, August 2026

    August 12, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Annuity Sales Set New Quarterly Record in Second Quarter

      August 3, 2026

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    “Bet The Under”: Hedge Fund Manager Makes Costly Mistake

    Secondary Life Markets May 12, 2023By Jay Olshansky
    Bet the under
    Share
    Twitter LinkedIn Email

    In 2009 my colleague and I were contacted by a hedge fund manager in New York City that was interested in investing in life settlements. He is well known, but I’ll protect his identity to save him the embarrassment about to be revealed. We were flown out to NYC and visited his lavish board room where there were a half dozen people in the room accompanying the hedge fund manager.

    They were considering an investment in a large portfolio of lives offered by a bank and wanted to know if we had insights on how long these people were likely to live. The investment was an over/under “bet” – they needed to decide whether there would be fewer or more deaths per month than predicted by the bank offering the investment.

    A 3-page brief describing the specifics of the investment was placed before us, including most importantly the assumptions used by the bank to generate the monthly survival estimates.

    Normally it might have taken some time to draw a conclusion about such a request, but in this case, my colleague and I looked up after just a few minutes reading the brief and we both said simultaneously – “bet the under”.

    Shocked at how quickly we arrived at our conclusion, the hedge fund manager said, “how do you know this?” Simple, I said, “the folks at the bank used life tables that were out-of-date – this is a slam dunk”.

    The tables were not just mildly out of date, they were based on data that was more than a decade old. Since we knew that death rates for the U.S. population declined rapidly in that decade, that meant the bank was overestimating mortality and underestimating survival by a lot. More people would survive each month relative to the prediction made by the bank. The speed and confidence we exuded in our answer unnerved the folks in the room more than just a little.

    The skeptical hedge fund manager blurted out “what if some of these folks live forever?” They won’t, we said, they’ll all die. “What if some live to 120 or 130?” “It’s highly unlikely”, we said, “the timing of death in humans is highly predictable and only one person in history lived past 120”. The hedge fund manager then went through a litany of medical breakthroughs that he believed are forthcoming, suggesting that there is great uncertainty in survival. It’s worth emphasizing that survival analysis was not his area of expertise; it is ours.

    Our response was “sure, these advances might happen, but even if they do, unless we find a way to modify the biological aging of our bodies, all the people in this investment pool will die out in a highly predictable way”. The folks in the room obviously had not read any of our published papers on the biological forces that govern human longevity and survival.

    I then asked the hedge fund manager two questions that really threw him and the other people in the room for a loop.

    The first was whether he could begin and end the investment whenever they wanted in a calendar year? The answer was yes, but he wanted to know why. I said, “If you bet the over, start the investment in November and end it in the month of February of some future year; if you bet the under, start the investment in March or April and end it in a future October. “Why” he asked. “Because of the seasonality of influenza deaths – which kill anywhere from 30,000 to 70,000 people every year in the U.S. (notwithstanding COVID-19). In this way you can juice up the return on your investment by using nothing more than timing.” They had no clue!

    The second question was whether the bank reported on the chronological age of the individuals, or did they have dates of birth. “Why” he asked. “If you bet the over, cherry pick the cohort for people born in the same year, to include people born earlier in the year like January through March; if you bet the under, cherry pick the cohort to include people born later in the year like October through December.” The reason should be obvious – people born earlier in the year are older than people born later in the same calendar year.

    At older ages, this can make a notable difference in survival. For an investment cohort of this size, using this information had the potential to juice returns even further. Jaws were dropping right and left at this suggestion. Again, they had no clue!

    What happened after we left?

    The hedge fund manager didn’t believe us, so they didn’t make the investment. We were able to track the survival trajectory of the investment cohort for the next year, and sure enough, there were many fewer deaths each month than predicted by the bank. This was a classic case of “adverse selection” where we had information on survival that the bank apparently either didn’t have or didn’t pay attention to.

    The hedge fund manager and his associates were extremely cautious, and we got that, but we handed them a golden goose of adverse selection on a silver platter and their arrogance and misinformation led them astray. They could have made a killing on that investment if you’ll excuse the play on words. My colleague and I would have bet our retirement funds on the under.

    S. Jay Olshansky is Chief Scientist and Co-Founder at Lapetus Solutions


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - May Commentary Life Settlements Longevity Risk Volume 2 Issue 5 - May 2023
    Share. Twitter LinkedIn Email

    Related Posts

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026By LMI Newsdesk

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026By Greg Winterton

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026By Fergus Bescoby

    Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

    August 6, 2026By LMI Newsdesk
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.